Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 18, 2006 Brian Lawler	Is a Buyback the Best Abbott Can Do? Abbott Labs may be out of ideas for its cash. Investors, take note.
The Motley Fool June 29, 2010 Brian Orelli	Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
The Motley Fool May 21, 2010 Brian Orelli	Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.
Bank Technology News October 2001 Daniel Joelson	AT&T Takes Big Bites in Latin America Despite making headway, the telecom giant is learning Latin America presents its own unique challenges...
The Motley Fool January 8, 2008 Brian Orelli	Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill.
The Motley Fool April 12, 2004 Brian Gorman	Abbott Not Rewarded Abbott Laboratories first-quarter earnings news was positive, but investors didn't react enthusiastically.
The Motley Fool January 31, 2007 Brian Lawler	You're Only Hurting Yourself, Thailand Thailand's decision to allow generics could do more harm than good. Investors, take note.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool March 20, 2007 Brian Lawler	Smart Move by Abbott? Abbott takes a drastic measure to make a point about its patents. Thailand's actions offer a good warning of what can happen when governments try to intervene too much in existing markets.
Global Services September 30, 2008 Imrana Khan	Latin America MSS Market Set to Grow to $332.7 Million by 2013 In the current market scenario, the outsourcing of network security in the region is now being accepted at a larger pace. Thus, Latin American IT-services providers are leveraging full outsourcing agreements.
The Motley Fool May 11, 2010 Brian Orelli	Abbott Makes a Push Into Selling Leftovers Abbott Labs has jumped on the established-product-division bandwagon. The company has licensed 24 products from Zydus Cadila of India and has the option to market another 40.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool February 20, 2008 Brian Orelli	Abbott's Copycat Combinations Abbott's latest FDA approval is for Simcor, a combination of Niaspan -- Abbott's slow-release niacin -- and the active component of Merck's Zocor, which isn't patent-protected anymore. Investors take note.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
The Motley Fool January 18, 2005 Stephen D. Simpson	Abbott Still Looks Healthy Never a too-big roaring growth stock or a too-small low-growth behemoth, the medical products company seems just right as it dependably keeps on performing for investors.
The Motley Fool December 18, 2008 Brian Orelli	A Diagnostic Tongue Twister Back-scratch fever between Abbott and Isis.
Pharmaceutical Executive August 1, 2014	Country Report: Chile 2014 kicks off a defining period for healthcare in Chile as a new national drug law is implemented
The Motley Fool February 21, 2008 Brian Orelli	Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
BusinessWeek January 29, 2007 Michael Arndt	Abbot Labs: Diagnosis: Shrewd Moves Abbott Laboratories has announced that it is selling about two-thirds of its $4 billion diagnostics business to buy more medical products outfits to help boost overall sales and profits by at least 10% a year into the next decade.
Managed Care November 2005	Recently Introduced Generics Helped Pbm Control Its Costs The top five generic drugs released over the past three years reduced pharmacy spending by 4.8 percent largely due to the timing of the release of generic products to the market.
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool January 19, 2011 Brian Orelli	A Painfully Protracted Partner Depomed is in a bind.
Knowledge@Wharton	Chile: A Beacon of Prosperity in a Turbulent Region Chile has chugged along. At a time of global frailties, its economy is healthier today than it has been over the past five years. What is behind Chile's success and can it be sustained?
The Motley Fool July 17, 2008 Brian Orelli	Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release
The Motley Fool August 3, 2004 Jeff Hwang	Generics Pump Watson The firm's strong growth in generic drug sales eases its branded product pains. The stock is up more than 10%.
The Motley Fool November 13, 2009 Brian Orelli	Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials.
The Motley Fool December 1, 2009 Brian Orelli	Abbott Makes All the Right Moves Hot off its cholesterol win over Merck, Abbott Labs is playing it safe with another cholesterol drug, TriCor.
The Motley Fool October 14, 2009 Brian Orelli	Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out.
BusinessWeek September 22, 2003	This Baby May Outdo Its Parent Some orphans are better off without their parents -- corporately speaking, that is. My hunch is this may apply to shares due to spring forth next year from health-care giant Abbott Laboratories.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
The Motley Fool July 31, 2009 Brian Orelli	Two Pictures of a Drug Company Who should we believe? The FDA? Mylan's earnings report?
Financial Planning November 1, 2011 Donald Jay Korn	The Latin Quarter Fortunately, unleveraged exposure to the region has been more than ample over the past decade. Planners with clients who can live with volatility might want to look south of the border.
The Motley Fool October 11, 2010 Brian Orelli	What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third...
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
The Motley Fool March 10, 2010 Brian Orelli	You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't.
Bank Systems & Technology April 28, 2008 Sherree DeCovny	JPMorgan Chase Extends Treasury & Securities Services in Latin America Responding to Latin America's expanding economy and growing export business, New York-based JPMorgan Chase has restructured its Treasury & Securities Services franchise to place an increased emphasis on the region.
The Motley Fool November 13, 2006 Brian Lawler	Kos' Swan Song The drug company releases what will probably be its last earnings announcement before a buyout by Abbot Labs. Investors, take note.
The Motley Fool December 16, 2008 Brian Orelli	Doubling Up on Triple Lipid Drugs The Food and Drug Administration gave Abbott Lab's TriLipix the thumbs-up, approving it for use by itself or with statins.
The Motley Fool January 25, 2006 Stephen D. Simpson	Abbott Wins No matter what Boston Scientific does with Guidant, Abbott looks like a winner. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry.
The Motley Fool July 15, 2009 Brian Orelli	Less Inflammation From Abbott's Quarter Humira is headed back in the right direction.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
The Motley Fool November 28, 2007 Nathan Parmelee	A Sea of Tranquility in a Financial Storm Some of the strongest economies in the world can now be found in Latin America, where companies have been largely immune to the volatility most companies around the world have experienced.
The Motley Fool July 19, 2007 Brian Lawler	Abbott on Top Abbott announces second-quarter financial results. Shares of Abbott aren't particularly expensive, considering the growth potential for its top compounds and its strong drug pipeline with compounds in development for several blockbuster indications.
The Motley Fool January 30, 2007 Brian Lawler	Is Bigger Better for Abbott Labs? Abbott continues its transformation into a more focused pharmaceutical powerhouse. But shares of this pharmaceutical aren't exactly cheap.
The Motley Fool November 15, 2011 Dan Caplinger	Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares.